Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Cancer·2026

Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026

Same author

SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia·2026

Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026

Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026

Same author

Early radiographic accuracy and intra-operative parameters of patient-specific instrumentation versus conventional technique in knee osteotomies for adolescent deformity correction: A prospective comparative study.

Journal of clinical orthopaedics and trauma·2026

Search research articles

Related Experiment Video

Updated: May 22, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

Peter L Greenberg¹, Richard M Stone², Yasmin Abaza³

¹Stanford Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN

|March 12, 2025

Summary

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) offer updated care recommendations. These insights cover new treatments for lower-risk and higher-risk MDS, plus emerging therapeutic agents.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

Related Experiment Videos

Last Updated: May 22, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

Area of Science:

Hematology
Oncology
Clinical Guidelines

Background:

Myelodysplastic Syndromes (MDS) require updated management strategies.
Recent clinical evidence has significantly advanced MDS treatment and understanding of prognostic factors.

Purpose of the Study:

To present the latest NCCN Guidelines for Myelodysplastic Syndromes (MDS).
To summarize recent evidence impacting MDS evaluation, diagnosis, and comprehensive patient care.

Main Methods:

Annual review of emerging clinical evidence and biologic factors by a multidisciplinary panel of MDS experts.
Evaluation of new data to inform treatment recommendations and prognostic significance.

Main Results:

Updated treatment recommendations for both lower-risk and higher-risk MDS.
Preference stratification of therapeutic agents based on new evidence.
Inclusion of emerging data on novel therapeutics.

Conclusions:

The NCCN Guidelines provide current, evidence-based recommendations for MDS management.
The updates reflect significant advances in understanding and treating MDS.
Expert consensus guides the integration of novel therapies into clinical practice.